128 related articles for article (PubMed ID: 25707626)
1. Targeted therapies: Hippo effector YAP1 inhibition—towards a new therapeutic option to overcome drug resistance.
Errico A
Nat Rev Clin Oncol; 2015 Apr; 12(4):190. PubMed ID: 25707626
[No Abstract] [Full Text] [Related]
2. YAP in MAPK pathway targeted therapy resistance.
Flaherty KT; Wargo JA; Bivona TG
Cell Cycle; 2015; 14(12):1765-6. PubMed ID: 26036142
[No Abstract] [Full Text] [Related]
3. YAP and the drug resistance highway.
Keren-Paz A; Emmanuel R; Samuels Y
Nat Genet; 2015 Mar; 47(3):193-4. PubMed ID: 25711863
[TBL] [Abstract][Full Text] [Related]
4. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.
Lin L; Sabnis AJ; Chan E; Olivas V; Cade L; Pazarentzos E; Asthana S; Neel D; Yan JJ; Lu X; Pham L; Wang MM; Karachaliou N; Cao MG; Manzano JL; Ramirez JL; Torres JM; Buttitta F; Rudin CM; Collisson EA; Algazi A; Robinson E; Osman I; Muñoz-Couselo E; Cortes J; Frederick DT; Cooper ZA; McMahon M; Marchetti A; Rosell R; Flaherty KT; Wargo JA; Bivona TG
Nat Genet; 2015 Mar; 47(3):250-6. PubMed ID: 25665005
[TBL] [Abstract][Full Text] [Related]
5. YAP1 expression in myelodysplastic syndromes and acute leukemias.
Machado-Neto JA; de Melo Campos P; Olalla Saad ST; Traina F
Leuk Lymphoma; 2014 Oct; 55(10):2413-5. PubMed ID: 24605912
[No Abstract] [Full Text] [Related]
6. MST1/2 and YAP1 gene expression in acute myeloid leukemia.
Safari S; Movafagh A; Zare-Adollahi D; Ghadiani M; Riazi-Isfahani S; Safavi-Naini N; Omrani MD
Leuk Lymphoma; 2014 Sep; 55(9):2189-91. PubMed ID: 24303784
[No Abstract] [Full Text] [Related]
7. Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers.
Cottini F; Hideshima T; Xu C; Sattler M; Dori M; Agnelli L; ten Hacken E; Bertilaccio MT; Antonini E; Neri A; Ponzoni M; Marcatti M; Richardson PG; Carrasco R; Kimmelman AC; Wong KK; Caligaris-Cappio F; Blandino G; Kuehl WM; Anderson KC; Tonon G
Nat Med; 2014 Jun; 20(6):599-606. PubMed ID: 24813251
[TBL] [Abstract][Full Text] [Related]
8. From targeted monotherapy to combined BRAF-MEK inhibitors and integrated genome analysis for melanoma treatment.
Roukos DH; Papaloukas C; Tzaphlidou M
Future Oncol; 2013 Jan; 9(1):5-8. PubMed ID: 23252557
[No Abstract] [Full Text] [Related]
9. In melanoma, Hippo signaling is affected by copy number alterations and YAP1 overexpression impairs patient survival.
Menzel M; Meckbach D; Weide B; Toussaint NC; Schilbach K; Noor S; Eigentler T; Ikenberg K; Busch C; Quintanilla-Martinez L; Kohlhofer U; Göke A; Göke F; Handgretinger R; Ottmann C; Bastian BC; Garbe C; Röcken M; Perner S; Kohlbacher O; Bauer J
Pigment Cell Melanoma Res; 2014 Jul; 27(4):671-3. PubMed ID: 24703331
[No Abstract] [Full Text] [Related]
10. Targeting the RAF-MEK-ERK pathway in cancer therapy.
Montagut C; Settleman J
Cancer Lett; 2009 Oct; 283(2):125-34. PubMed ID: 19217204
[TBL] [Abstract][Full Text] [Related]
11. Development: Hippo signalling turns the embryo inside out.
Manzanares M; Rodriguez TA
Curr Biol; 2013 Jul; 23(13):R559-61. PubMed ID: 23845241
[TBL] [Abstract][Full Text] [Related]
12. How cutaneous eruptions help to understand the mode of action of kinase inhibitors.
Dummer R; Tsao H; Robert C
Br J Dermatol; 2012 Nov; 167(5):965-7. PubMed ID: 23106351
[No Abstract] [Full Text] [Related]
13. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
14. Involvement of Janus kinases, p52shc, Raf-1, and MEK-1 in the IL-6-induced mitogen-activated protein kinase cascade of a growth-responsive B cell line.
Kumar G; Gupta S; Wang S; Nel AE
J Immunol; 1994 Nov; 153(10):4436-47. PubMed ID: 7963520
[TBL] [Abstract][Full Text] [Related]
15. Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600-mutated melanoma.
Amann VC; Hoffmann D; Mangana J; Dummer R; Goldinger SM
J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1638-1640. PubMed ID: 28401596
[TBL] [Abstract][Full Text] [Related]
16. MEK Inhibition Enhances Preclinical Activity of BRAF Inhibition and Immunotherapy.
Cancer Discov; 2015 May; 5(5):OF12. PubMed ID: 25813351
[No Abstract] [Full Text] [Related]
17. Combination of RAF and MEK inhibition for the treatment of BRAF-mutated melanoma: feedback is not encouraged.
Chapman PB; Solit DB; Rosen N
Cancer Cell; 2014 Nov; 26(5):603-4. PubMed ID: 25517746
[TBL] [Abstract][Full Text] [Related]
18. BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma.
Niessner H; Sinnberg T; Kosnopfel C; Smalley KSM; Beck D; Praetorius C; Mai M; Beissert S; Kulms D; Schaller M; Garbe C; Flaherty KT; Westphal D; Wanke I; Meier F
Clin Cancer Res; 2017 Oct; 23(20):6203-6214. PubMed ID: 28724666
[No Abstract] [Full Text] [Related]
19. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
Morris EJ; Jha S; Restaino CR; Dayananth P; Zhu H; Cooper A; Carr D; Deng Y; Jin W; Black S; Long B; Liu J; Dinunzio E; Windsor W; Zhang R; Zhao S; Angagaw MH; Pinheiro EM; Desai J; Xiao L; Shipps G; Hruza A; Wang J; Kelly J; Paliwal S; Gao X; Babu BS; Zhu L; Daublain P; Zhang L; Lutterbach BA; Pelletier MR; Philippar U; Siliphaivanh P; Witter D; Kirschmeier P; Bishop WR; Hicklin D; Gilliland DG; Jayaraman L; Zawel L; Fawell S; Samatar AA
Cancer Discov; 2013 Jul; 3(7):742-50. PubMed ID: 23614898
[TBL] [Abstract][Full Text] [Related]
20. MEK and RAF inhibitors for BRAF-mutated cancers.
Belden S; Flaherty KT
Expert Rev Mol Med; 2012 Oct; 14():e17. PubMed ID: 23058743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
